David Gallinson

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +11

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque et al. · ESMO Open · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacology +17

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque et al. · Annals of Oncology · 2019 · 59 citations · Full text

Medicine, Oncology, Pharmacology +13

Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer

Johanna C. Bendell, Thomas J. Ervin, David Gallinson et al. · Clinical Colorectal Cancer · 2013 · 34 citations

Medicine, Oncology, Pharmacotherapy +12

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · Journal of Clinical Oncology · 2021 · 25 citations

Medicine, Pharmacology, Pharmacotherapy +13